These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 15245508)

  • 1. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
    Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2004 Aug; 73(2):98-103. PubMed ID: 15245508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.
    Palumbo A; Giaccone L; Bertola A; Pregno P; Bringhen S; Rus C; Triolo S; Gallo E; Pileri A; Boccadoro M
    Haematologica; 2001 Apr; 86(4):399-403. PubMed ID: 11325646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Plasmati R; Cangini D; Tacchetti P; Perrone G; Pastorelli F; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2005 Mar; 74(3):212-6. PubMed ID: 15693790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
    Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M
    Haematologica; 2002 Apr; 87(4):408-14. PubMed ID: 11940485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
    Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Poser M; Müller S; Flasshove M; Moritz T; Seeber S; Nowrousian MR
    Ann Hematol; 2005 Sep; 84(9):594-600. PubMed ID: 15744524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years.
    Matsue K; Fujiwara H; Iwama K; Kimura S; Yamakura M; Takeuchi M
    Ann Hematol; 2010 Mar; 89(3):291-7. PubMed ID: 19693498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
    Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
    Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
    Offidani M; Corvatta L; Marconi M; Visani G; Alesiani F; Brunori M; Galieni P; Catarini M; Burattini M; Centurioni R; Rupoli S; Scortechini AR; Giuliodori L; Candela M; Capelli D; Montanari M; Olivieri A; Piersantelli MN; Leoni P
    Haematologica; 2006 Jan; 91(1):133-6. PubMed ID: 16434383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
    Lee SS; Suh C; Kim BS; Chung J; Joo YD; Ryoo HM; Do YR; Jin JY; Kang HJ; Lee GW; Lee MH; Shim H; Kim K; Yoon SS; Bang SM; Kim HY; Lee JJ; Park J; Lee DS; Lee JH;
    Ann Hematol; 2010 Sep; 89(9):905-12. PubMed ID: 20349060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
    Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
    J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
    Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
    Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
    Steurer M; Spizzo G; Mitterer M; Gastl G
    Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
    Rajkumar SV; Blood E; Vesole D; Fonseca R; Greipp PR;
    J Clin Oncol; 2006 Jan; 24(3):431-6. PubMed ID: 16365178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
    Kim YK; Sohn SK; Lee JH; Yang DH; Moon JH; Ahn JS; Kim HJ; Lee JJ;
    Ann Hematol; 2010 May; 89(5):475-82. PubMed ID: 19921192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
    Badros AZ; Goloubeva O; Rapoport AP; Ratterree B; Gahres N; Meisenberg B; Takebe N; Heyman M; Zwiebel J; Streicher H; Gocke CD; Tomic D; Flaws JA; Zhang B; Fenton RG
    J Clin Oncol; 2005 Jun; 23(18):4089-99. PubMed ID: 15867202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.